FMX103 minocycline foam 1.5% + Vehicle foam
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Facial Papulopustular Rosacea
Conditions
Facial Papulopustular Rosacea
Trial Timeline
Jun 2, 2017 → Sep 28, 2018
NCT ID
NCT03142451About FMX103 minocycline foam 1.5% + Vehicle foam
FMX103 minocycline foam 1.5% + Vehicle foam is a phase 3 stage product being developed by Vyne Therapeutics for Facial Papulopustular Rosacea. The current trial status is completed. This product is registered under clinical trial identifier NCT03142451. Target conditions include Facial Papulopustular Rosacea.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03142451 | Phase 3 | Completed |
| NCT04608500 | Phase 3 | Completed |
Competing Products
13 competing products in Facial Papulopustular Rosacea
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BOTOX | AbbVie | Approved | 85 |
| OnabotulinumtoxinA + KYBELLA | AbbVie | Approved | 85 |
| BOTOX®/VISTABEL® | AbbVie | Approved | 85 |
| Erenumab Prefilled Syringe | Amgen | Approved | 84 |
| Rapamune | Pfizer | Phase 1 | 32 |
| EMLA Cream | Sanofi | Phase 3 | 76 |
| Diflucortolone valerate (BAY866146) | Bayer | Pre-clinical | 20 |
| Botulinum toxin type A | Ipsen | Phase 3 | 74 |
| IPN10200 + IPN10200 Placebo + Dysport | Ipsen | Phase 1/2 | 38 |
| IPN59011 + Azzalure + Placebo | Ipsen | Phase 1 | 30 |
| Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4) | Baxter | Phase 2 | 49 |
| Metyrosine + Placebo | Bausch Health | Phase 2 | 47 |
| FMX103 minocycline foam 1.5% + Vehicle foam | Vyne Therapeutics | Phase 3 | 69 |